The new protein treatment shows the promise as the first antidote to poisoning with carbon oxide

The Umsom University College researchers, along with their colleagues, designed a new molecule that seems promising as an effective antidote to carbon monoxide poisoning with lower side effects than other molecules that are currently tested, according to a new study Published In the magazine pnas.

Carbon monoxide poisoning is 50,000 visits in the United States Emergency Room every year and cause about 1500 deaths. These deaths may occur when carbon monoxide accumulates from combustion in a closed space, which can result from ventilation failure in internal natural gas burning equipment, or operating gasoline generators or cars at home or in a closed garage. Carbon monoxide poisoning is also associated with most fires from inhalation of smoke.

Currently, the only treatments for carbon monoxide poisoning are oxygen -based treatments, which help the body get rid of toxic gas. However, even with treatment, nearly half of the survivors suffer from heart and brain damage in the long run. This has created an urgent need for faster and more effective treatments.

In the new study, the research team has developed a new protein-based treatment called RCOCCOM-HBD-CCC, which works as a sponge to shower carbon monoxide from the blood. Starting with RCOM (abbreviation for “metabolism organizer”) – natural protein uses that the bacteria Paraburkholderia Xenovorans uses accurate levels of carbon monoxide – the researchers have designed a very selective version: it holds the first carbon monoxide without interfering with oxygen or other important molecules in the body.

In tests on mice, the new treatment is quickly to remove carbon monoxide from red blood cells and was safely wiped from the body through the urine. The corresponding author said, Mark T. Gladwin: “Unlike other protein -based treatments, we found that the compound had only had little changes in blood pressure, which was an exciting discovery and raised the possibility that this new molecule had clinical applications.”

“This has the ability to become an intravenous vein for the first carbon monoxide that can be given in the emergency department or even in this field by the first respondents.”

How to kill carbon monoxide

In healthy bodies, inhaled oxygen from the air is associated with protein, on the surface of red blood cells, which transports oxygen to all body tissues. However, the toxic carbon monoxide gas that inhales is competing with the oxygen for hemoglobin. It enters the bloodstream and is associated with hemoglobin with close to 200 to 400 times of oxygen. This means that the first carbon monoxide pigs most hemoglobin seats, so oxygen molecules cannot reach the tissues you need.

Currently, the only treatments available for carbon monoxide poisoning include giving 100 % pure oxen, sometimes under pressure in an excessive room.

Often, patients are not transported, diagnosed and treated in a timely manner to reflect the effects of carbon monoxide poisoning, which can cause permanent heart and nerve injuries or even death.

Jason J. said. Rose, one of the study researchers: “This molecule can be a changing games because it can directly and quickly remove carbon monoxide from the body with this low risk of side effects outside the target.” “Given the promising results, we also see the possibility of using the RCCOM-HBD-CCC in other areas, such as an alternative to severe anemia or hemorrhagic shock.”

Blood jubilee

The research team focused on the first carbon monoxide engineering, which resembles protein in a hemoglobin structural standard, known as hemoprat proteins, but shows larger convergence – to the first carbon monoxide, and the lower convergence of binding oxygen.

Zublots in the bloodstream, such as RCCOM-HBD-CCC, are quickly associated with carbon monoxide molecules, which reduces the time it takes to wipe the first carbon monoxide in the blood to less than a minute, compared to more than an hour with pure oxygen treatment and five hours without any treatment. When the first carbon monoxide is cleared, this hemoglobin is released on red blood cells to start carrying oxygen again.

But many hemops proteins also share some convergence with binding oxygen, and therefore can also turn on nitric oxide, an important molecule in regulating blood pressure. Protein or hemoglobin batches can reduce nitric oxide levels, which leads to tightening blood vessels and a rapid rise in blood pressure.

In this last study, the researchers were surprised when it was found that the RCCOM-HBD-CCC did not lead to an increase in blood pressure, regardless of whether carbon monoxide is present in the blood. They see that although RCCOM-HBD-CCC may divide nitric oxide, which is a blood pressure regulator molecule, it may do this slowly more than other proteins, which leads to his safer personal file.

Future studies may include more pre-clinical research to determine the scope of the safe and effective dose for the RCCOM-HBD-CCC in the treatment of carbon monoxide poisoning. It can also be a basis for new research in other areas, including treatment for oxygen delivery or a blood alternative. This can include hemorrhagic trauma, acute respiratory syndrome (ARDS), acute anemia, and organs to plant.

Dr. Rose and Din Gladwin are the founders and directors of Globin Solutions, who licensed ROC -based technology from the University of Pittsburg to develop poisoning poisoning. Dr. Rose is the president and CEO of Globin Solutions. Globin Solutions sponsored the research agreements with UMB.